Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients
Open accessAbstract
The current inability of psychiatric medicine to objectively select the most appropriate treatment or to predict imminent relapse are major factors contributing to the severity and clinical burden of schizophrenia. We have previously used multiplexed immunoassays to show that schizophrenia patients have a distinctive molecular signature in serum compared with healthy control subjects. In the present study, we used the same approach to measure biomarkers in a population of 77 schizophrenia patients who were followed up over 25 months with four aims: (1) to identify molecules associated with symptom severity in antipsychotic naive and unmedicated patients, (2) to determine biomarker signatures that could predict response over a 6-week treatment period, (3) to identify molecular panels that could predict the time to relapse in a cross-sectional population of patients in remission and (4) to investigate how the biological relapse signature changed throughout the treatment course. This led to identification of molecular signatures that could predict symptom improvement over the first 6 weeks of treatment as well as predict time to relapse in a subset of 18 patients who experienced recurrence of symptoms. This study provides the groundwork for the development of novel objective clinical tests that can help psychiatrists in the clinical management of schizophrenia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Interleukin 16 protein levels have been reported to be altered in serum samples of MDD patients and to be associated with symptom severity in schizophrenia.
“interleukin 16 protein levels have been reported to be altered in a molecular profiling study on serum samples of MDD patients (Stelzhammer et al., 2014) and to be associated with symptom severity in schizophrenia (Schwarz et al., 2012).”
From Epigenome-wide DNA methylation in unipolar depression: predictive biomarker of antidepressant treatment response? (2024) · cites this paper as Schwarz et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538 · see citing works
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
Regression to the mean: what it is and how to deal with it
Barnett, A. G. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh299 · Cited by 1,988 · see citing works
Chakos, M., Lieberman, J. A., Hoffman, E. B., Bradford, D. W., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 632 · see citing works
Statistic Notes: Regression towards the mean
Bland, J. M., & Altman, D. G. (1994) · BMJ · doi:10.1136/bmj.308.6942.1499 · Cited by 547 · see citing works
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387 · see citing works
The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients
Meltzer, H. Y. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770030003001 · Cited by 294 · see citing works
The metabolic syndrome and schizophrenia
Meyer, J. M., & Stahl, S. M. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01317.x · Cited by 244 · see citing works
Effects of antipsychotics on fat deposition and changes in leptin and insulin levels
Zhang, Z., Yao, Z., Liu, W., Fang, Q., & Reynolds, G. P. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.184.1.58 · Cited by 230 · see citing works
Identification of a biological signature for schizophrenia in serum
Schwarz, E., Guest, P. C., Rahmoune, H., Harris, L. W., Wang, L., Leweke, F. M., Rothermundt, M., Bogerts, B., Koethe, D., Kranaster, L., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.42 · Cited by 223 · see citing works
Self-citationAntipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association
Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00003 · Cited by 185 · see citing works
Arranz, B., Rosel, P., Ramírez, N. D., Dueñas, R., Fernández, P., Sanchez, J. M., Navarro, M. A., & San, L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1007 · Cited by 161 · see citing works
Schwarz, E., Izmailov, R., Spain, M., Barnes, A., Mapes, J. P., Guest, P. C., Rahmoune, H., Pietsch, S., Leweke, F. M., Rothermundt, M., et al. (2010) · Biomarker Insights · doi:10.4137/bmi.s4877 · Cited by 160 · see citing works
Self-citationBossuyt, P. M., & Reitsma, J. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12122-8 · Cited by 146 · see citing works
Clozapine-induced weight gain predicts improvement in psychopathology
Meltzer, H. Y., Perry, E. B., & Jayathilake, K. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00326-7 · Cited by 145 · see citing works
Guest, P. C., Schwarz, E., Krishnamurthy, D., Harris, L. W., Leweke, F. M., Rothermundt, M., van Beveren, N. J. M., Spain, M. G., Barnes, A., Steiner, J. H., et al. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.12.018 · Cited by 138 · see citing works
Self-citationWong, E. H. F., Yocca, F. D., Smith, M. A., & Lee, C. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000866 · Cited by 133 · see citing works
Guest, P. C., Wang, L., Harris, L. W., Burling, K., Levin, Y., Ernst, A., Wayland, M. T., Umrania, Y., Herberth, M., Koethe, D., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.81 · Cited by 126 · see citing works
Self-citationEffects of atypical antipsychotics on weight and serum lipid levels.
Meyer, J. M. (2001) · PubMed · Cited by 118 · see citing works
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Butterfield, L. H., Palucka, A. K., Britten, C. M., Dhodapkar, M. V., Håkansson, L., Janetzki, S., Kawakami, Y., Kleen, T. O., Lee, P. P., Maccalli, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2234 · Cited by 108 · see citing works
Altered Levels of Acute Phase Proteins in the Plasma of Patients with Schizophrenia
Yang, Y., Wan, C., Li, H., Zhu, H., La, Y., Xi, Z., Chen, Y., Jiang, L., Feng, G., & He, L. (2006) · Analytical Chemistry · doi:10.1021/ac051916x · Cited by 103 · see citing works
Modeling treatment-resistant depression
Samuels, B. A., Leonardo, E. D., Gadient, R. A., Williams, A., Zhou, J., David, D. J. P., Gardier, A. M., Wong, E. H. F., & Hen, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.017 · Cited by 87 · see citing works
Pannacciulli, N., Le, D. S. N. T., Chen, K., Reiman, E. M., & Krakoff, J. A. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.019 · Cited by 77 · see citing works
Is leptin the link between obesity and insulin resistance?
Girard, J. R. (1997) · PubMed · Cited by 76 · see citing works
Pharmacotherapy for treatment-resistant schizophrenia
Harrison, J., McIlwain, M., Wheeler, A., & Russell (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12769 · Cited by 67 · see citing works
Meltzer, H., Lee, M., & Jayathilake, K. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00201-3 · Cited by 56 · see citing works
Kajikawa, Y., Ikeda, M., Takemoto, S., Tomoda, J., Ohmaru, N., & Kusachi, S. (2011) · International Heart Journal · doi:10.1536/ihj.52.17 · Cited by 53 · see citing works
Body Weight and Plasma Levels of Ghrelin and Leptin during Treatment with Olanzapine
Kim, B., Sohn, J., Park, C., Hahn, G.-H., Koo, J. B., Noh, Y.-D., & Lee, C.-S. (2008) · Journal of Korean Medical Science · doi:10.3346/jkms.2008.23.4.685 · Cited by 37 · see citing works
Personalized Medicine — Trends in Molecular Diagnosticsy
Hoggatt, J. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03257193 · Cited by 30 · see citing works
Hoggatt, J. (2011) · PubMed · doi:10.2165/11534880-000000000-00000 · Cited by 30 · see citing works
Buckley, P. F., Krowinski, A. C., Miller, D. D., Friedman, L., Eaton, Y., & Tronetti, M. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00084-5 · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fernandes, B. S., Steiner, J., Bernstein, H.-G., Dodd, S., Pasco, J. A., Dean, O. M., Nardin, P., Gonçalves, C.-A., & Berk, M. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.87 · Cited by 348 · see citing works
Self-citationKiddle, S. J., Sattlecker, M., Proitsi, P., Simmons, A., Westman, E., Bazenet, C. E., Nelson, S. K., Williams, S., Hodges, A., Johnston, C., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130380 · Cited by 187 · see citing works
Neuroimmune biomarkers in schizophrenia
Tomasik, J., Rahmoune, H., Guest, P. C., & Bahn, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.07.025 · Cited by 158 · see citing works
Self-citationNascimento, J. M., & Martins‐de‐Souza, D. (2015) · Schizophrenia · doi:10.1038/npjschz.2014.3 · Cited by 125 · see citing works
Prata, J., Santos, S. G., Almeida, M. I., Coelho, R., & Barbosa, M. A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0938-y · Cited by 115 · see citing works
Raben, A., Marshe, V. S., Chintoh, A. F., Gorbovskaya, I., Müller, D. J., & Hahn, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00741 · Cited by 114 · see citing works
Theranostic Biomarkers for Schizophrenia
Perković, M. N., Erjavec, G. N., Štrac, D. Š., Uzun, S., Kozumplik, O., & Pivac, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040733 · Cited by 97 · see citing works
Comes, A. L., Papiol, S., Müeller, T., Geyer, P. E., Mann, M., & Schulze, T. G. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0219-2 · Cited by 101 · see citing works
Applications of blood-based protein biomarker strategies in the study of psychiatric disorders
Chan, M. K., Gottschalk, M. G., Haenisch, F., Tomasik, J., Ruland, T., Rahmoune, H., Guest, P. C., & Bahn, S. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.08.002 · Cited by 94 · see citing works
Self-citationProteomics Research in Schizophrenia
Davalieva, K., Kostovska, I. M., & Dwork, A. J. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00018 · Cited by 84 · see citing works
Tognin, S., van Hell, H. H., Merritt, K., Rossum, I. W.-V., Bossong, M. G., Kempton, M. J., Modinos, G., Fusar‐Poli, P., Mechelli, A., Dazzan, P., et al. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz067 · Cited by 82 · see citing works
Hayashi‐Takagi, A., Vawter, M. P., & Iwamoto, K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.09.035 · Cited by 80 · see citing works
Biomarker Approaches in Major Depressive Disorder Evaluated in the Context of Current Hypotheses
Jentsch, M., van Buel, E. M., Bosker, F. J., Gladkevich, A. V., Klein, H. C., Voshaar, R. C. O., Ruhé, H. G., Eisel, U. L., & Schoevers, R. A. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.114 · Cited by 79 · see citing works
Berger, M., Juster, R., Westphal, S., Amminger, G. P., Bogerts, B., Schiltz, K., Bahn, S., Steiner, J. H., & Sarnyai, Z. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.02.001 · Cited by 74 · see citing works
Self-citationMaking Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research
Guest, P. C., Guest, F. L., & Martins‐de‐Souza, D. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv138 · Cited by 63 · see citing works
Self-citationBousman, C., Maruf, A. A., Marques, D. F., Brown, L. C., & Müller, D. J. (2023) · Psychological Medicine · doi:10.1017/s0033291723002817 · Cited by 60 · see citing works
Jordan, W., Dobrowolny, H., Bahn, S., Bernstein, H., Brigadski, T., Frodl, T., Isermann, B., Leßmann, V., Pilz, J., Rodenbeck, A., et al. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0749-7 · Cited by 58 · see citing works
Self-citationVeronese, M., Santangelo, B., Jauhar, S., D’Ambrosio, E., Demjaha, A., Salimbeni, H., Jin, H., McCrone, P., Turkheimer, F., & Howes, O. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00866-7 · Cited by 58 · see citing works
Systems Biology, Bioinformatics, and Biomarkers in Neuropsychiatry
Alawieh, A. M., Zaraket, F. A., Li, J., Mondello, S., Nokkari, A., Razafsha, M., Fadlallah, B. H., Boustany, R., & Kobeissy, F. H. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00187 · Cited by 49 · see citing works
Fernandes, B. S., Dai, Y., Jia, P., & Zhao, Z. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.06.001 · Cited by 48 · see citing works
Impaired Metabolic Reactivity to Oxidative Stress in Early Psychosis Patients
Fournier, M., Ferrari, C., Baumann, P. S., Polari, A., Monin, A., Bellier-Teichmann, T., Wulff, J., Pappan, K. L., Cuenod, M., Conus, P., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu053 · Cited by 48 · see citing works
Thompson, J. R., Gustafsson, H., DeCapo, M., Takahashi, D. L., Bagley, J. L., Dean, T. A., Kievit, P., Fair, D. A., & Sullivan, E. L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00161 · Cited by 45 · see citing works
Cooper, J. D., Özcan, S., Gardner, R. M., Rustogi, N., Wicks, S., van Rees, G. F., Leweke, F. M., Dalman, C., Karlsson, H., & Bahn, S. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0027-0 · Cited by 44 · see citing works
Self-citationMäntylä, T. J. S., Mantere, O., Raij, T. T., Kieseppä, T., Laitinen, H. K., Leiviskä, J., Torniainen, M., Tuominen, L. J., Vaarala, O., & Suvisaari, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125112 · Cited by 41 · see citing works
Schmitt, A., Martins‐de‐Souza, D., Akbarian, S., Cassoli, J. S., Ehrenreich, H., Fischer, A., Fonteh, A. N., Gattaz, W. F., Gawlik, M., Gerlach, M., et al. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1224929 · Cited by 41 · see citing works
Self-citationThe neurobiology of relapse in schizophrenia
Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 38 · see citing works
Schubert, K. O., Clark, S. R., & Baune, B. T. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414560650 · Cited by 36 · see citing works
Guest, F. L., Guest, P. C., & Martins‐de‐Souza, D. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2015-0055 · Cited by 36 · see citing works
Self-citationThe use of Proteomic Biomarkers for Improved Diagnosis and Stratification Of Schizophrenia Patients
Guest, P. C., Chan, M. K., Gottschalk, M. G., & Bahn, S. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.83 · Cited by 34 · see citing works
Self-citationPharmaco-Multiomics: A New Frontier in Precision Psychiatry
Dhieb, D., & Bastaki, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031082 · Cited by 33 · see citing works
Realising stratified psychiatry using multidimensional signatures and trajectories
Joyce, D. W., Kehagia, A. A., Tracy, D. K., Proctor, J., & Shergill, S. S. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1116-1 · Cited by 31 · see citing works
The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets
Lago, S. G., & Bahn, S. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00290-4 · Cited by 30 · see citing works
Self-citationAquino, A., Alexandrino, G. L., Guest, P. C., Augusto, F., Gomes, A. F., Murgu, M., Steiner, J. H., & Martins‐de‐Souza, D. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00209 · Cited by 29 · see citing works
Self-citationProteomic Differences in Blood Plasma Associated with Antidepressant Treatment Response
Turck, C. W., Guest, P. C., Maccarrone, G., Ising, M., Kloiber, S. M., Lucae, S., Holsboer, F., & Martins‐de‐Souza, D. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00272 · Cited by 29 · see citing works
Self-citationGiné-Servén, E., Martinez-Ramirez, M., Boix-Quintana, E., Daví-Loscos, E., Guanyabens, N., Casado, V., Muriana, D., Rivas, C. T., Crespo‐Facorro, B., & Labad, J. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110424 · Cited by 28 · see citing works
Tomasik, J., Schwarz, E., Lago, S. G., Rothermundt, M., Leweke, F. M., van Beveren, N. J. M., Guest, P. C., Rahmoune, H., Steiner, J. H., & Bahn, S. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.10.019 · Cited by 27 · see citing works
Self-citationTomasik, J., Schwarz, E., Guest, P. C., & Bahn, S. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0354-3 · Cited by 27 · see citing works
Self-citationLaurikainen, H., Vuorela, A., Toivonen, A., Reinert‐Hartwall, L., Trontti, K., Lindgren, M., Keinänen, J., Mäntylä, T. J. S., Paju, J., Ilonen, T., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0776-z · Cited by 27 · see citing works
Proteomic profiling in schizophrenia: enabling stratification for more effective treatment
Guest, P. C., Martins‐de‐Souza, D., Schwarz, E., Rahmoune, H., Alsaif, M., Tomasik, J., Turck, C. W., & Bahn, S. (2013) · Genome Medicine · doi:10.1186/gm429 · Cited by 26 · see citing works
Self-citationSimvastatin augmentation for recent-onset psychotic disorder: A study protocol
Begemann, M., Schutte, M. J. L., Slot, M. I. E., Doorduin, J., Bakker, P. R., van Haren, N. E. M., & Sommer, I. E. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.06.007 · Cited by 24 · see citing works
Zaki, J. K., Lago, S. G., Rustogi, N., Gangadin, S. S., Benáček, J., van Rees, G. F., Haenisch, F., Broek, J. A. C., Suárez‐Pinilla, P., Ruland, T., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02229-w · Cited by 23 · see citing works
Self-citationScreening of schizophrenia associated miRNAs and the regulation of miR-320a-3p on integrin β1
Wang, Y., Wang, J., Guo, T., Peng, Y., Wang, K., Bai, K., & Huang, Y. (2019) · Medicine · doi:10.1097/md.0000000000014332 · Cited by 23 · see citing works
Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia
Lago, S. G., & Bahn, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00205 · Cited by 22 · see citing works
Self-citationLevchenko, А., Nurgaliev, T., Kanapin, A. A., Samsonova, A. A., & Gainetdinov, R. R. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03990 · Cited by 20 · see citing works
Cassoli, J. S., Guest, P. C., Santana, A. G., & Martins‐de‐Souza, D. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500109 · Cited by 18 · see citing works
Self-citationMurck, H., LAUGHREN, T. P., Lamers, F., Picard, R. W., Walther, S., GOFF, D. C., & Sainati, S. M. (2015) · Europe PMC (PubMed Central) · doi:10.7892/boris.69085 · Cited by 17 · see citing works
Lamarckian evolution explains human brain evolution and psychiatric disorders
Barry, G. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00224 · Cited by 17 · see citing works
Garcia, S., Baldasso, P. A., Guest, P. C., & Martins‐de‐Souza, D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6730-8_16 · Cited by 17 · see citing works
Self-citationIdentifying Biomarker Candidates in the Blood Plasma or Serum Proteome
Garcia, S., Silva-Costa, L. C., Reis‐de‐Oliveira, G., Guest, P. C., Baldasso, P. A., Cassoli, J. S., & Martins‐de‐Souza, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_15 · Cited by 15 · see citing works
Self-citationBlood-Based Biomarkers in Depression: Emerging Themes in Clinical Research
Uddin, M. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0108-1 · Cited by 15 · see citing works
Use of Translational Pharmacodynamic Biomarkers in Early-Phase Clinical Studies for Schizophrenia
English, B. A., Thomas, K. L. H., Johnstone, J., Bazih, A., Gertsik, L., & Ereshefsky, L. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.135 · Cited by 15 · see citing works
Xu, R., Liang, J., Luo, Y., Wan, X., Li, K. C., Qi, L.-G., Yuan, W., Chen, J., Wu, Z., Wang, M., et al. (2018) · Medicine · doi:10.1097/md.0000000000013553 · Cited by 15 · see citing works
Martins‐de‐Souza, D., Guest, P. C., & Steiner, J. H. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01002-3 · Cited by 14 · see citing works
Self-citationSchiele, M. A., Crespo Salvador, O., Lipovsek, J., Schwarte, K., Schlosser, P., Zwanzger, P., Arolt, V., Baune, B. T., Köttgen, A., & Domschke, K. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae045 · Cited by 13 · see citing works
Llorca-Bofí, V., Madero, S., Amoretti, S., Cuesta, M. J., Moreno, C., González-Pinto, A., Bergé, D., Rodríguez–Jiménez, R., Roldán, A., García‐León, M. Á., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.03.011 · Cited by 13 · see citing works
Luckhoff, H. K., du Plessis, S. S., Scheffler, F., Phahladira, L., Kilian, S., Buckle, C., Smit, R., Chiliza, B., Asmal, L., & Emsley, R. A. (2020) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2020.111173 · Cited by 13 · see citing works
Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox
García‐Rizo, C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.560006 · Cited by 12 · see citing works
Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy
Chauhan, P., Kaur, G., Prasad, R., & Singh, H. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1994857 · Cited by 11 · see citing works
Steiner, J. H., Guest, P. C., Rahmoune, H., & Martins‐de‐Souza, D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6730-8_2 · Cited by 11 · see citing works
Self-citationSteiner, J. H., Guest, P. C., & Martins‐de‐Souza, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_1 · Cited by 10 · see citing works
Self-citationPsychotic relapse prediction via biomarker monitoring: a systematic review
Smyrnis, A., Theleritis, C. G., Ferentinos, P. P., & Smyrnis, N. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1463974 · Cited by 9 · see citing works
Berdeville, C. H. D. S. F., Silva-Amaral, D., Dalgalarrondo, P., Banzato, C. E. M., & Martins‐de‐Souza, D. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105949 · Cited by 9 · see citing works
Park, J.-S., Heo, H., Kim, M., Lee, S., Park, S.-K., Kim, K., Kang, Y.-H., Kim, J. S., Sung, Y. H., Shim, W. H., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02258-x · Cited by 8 · see citing works
Proteomics insight into psychiatric disorders: an update on biological fluid biomarkers
Giusti, L., Ciregia, F., Mazzoni, M. R., & Lucacchini, A. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1230499 · Cited by 8 · see citing works
Lab-on-a-Chip Proteomic Assays for Psychiatric Disorders
Peter, H., Wienke, J., Guest, P. C., Bistolas, N., & Bier, F. F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_33 · Cited by 7 · see citing works
Self-citationExploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia
Zaki, J. K., Lago, S. G., Spadaro, B., Rustogi, N., Gangadin, S. S., Benáček, J., Drexhage, H. A., de Witte, L. D., Kahn, R. S., Sommer, I. E., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.02.011 · Cited by 6 · see citing works
Self-citationMiyano, T., Hirouchi, M., Yoshimura, N., Hattori, K., Mikkaichi, T., & Kiyosawa, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413522 · Cited by 6 · see citing works
Clark, S. R., Schubert, K. O., Olagunju, A. T., Lyrtzis, E., & Baune, B. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00662 · Cited by 6 · see citing works
Li, Q., Su, Y., Liao, X., Fang, M., Gao, J., Xu, J., Duan, M., Yu, H., Yang, Y., Chen, Z., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1383173 · Cited by 5 · see citing works
Идентификация биомаркеров шизофрении с помощью методов масс-спектрометрии (обзор литературы)
Языкова, А. Б., Новоселова, А. Э., Царьков, И. Е., & Zhilyaeva, T. V. (2023) · Сибирский вестник психиатрии и наркологии · doi:10.26617/1810-3111-2023-1(118)-71-81 · Cited by 4 · see citing works
Peripheral Biomarkers for Depression by Plasma and Serum Proteomics
Domenici, E. (2014) · Advances in biological psychiatry · doi:10.1159/000358178 · Cited by 4 · see citing works
Yang, J., Li, Z., Fan, X., & Cheng, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094360 · Cited by 4 · see citing works
Golub, Y., Stonawski, V., Plank, A.-C., Eichler, A., Kratz, O., Waltes, R., von Hörsten, S., Roessner, V., & Freitag, C. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.644553 · Cited by 4 · see citing works
Smith, E. C. C., Au, E., Pereira, S., Sharma, E., Venkatasubramanian, G., Remington, G. J., Agarwal, S. M., & Hahn, M. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115472 · Cited by 4 · see citing works
Dissecting the Genetic Relationship Between Schizophrenia and Cardiovascular Disease
Strawbridge, R. J., & Graham, N. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230714 · Cited by 4 · see citing works
Can proteomics‐based diagnostics aid clinical psychiatry?
Filiou, M. D. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400144 · Cited by 3 · see citing works
Steiner, J. H., & Guest, P. C. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_21 · Cited by 3 · see citing works
Self-citationGiné-Servén, E., Boix-Quintana, E., Ballesteros, A., Daví-Loscos, E., Guanyabens, N., Casado, V., Martínez-Ramírez, M., Crespo‐Facorro, B., Cuesta, M. J., & Labad, J. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111336 · Cited by 2 · see citing works
Multimodal modeling for personalized psychiatry
Clark, S. R., Cearns, M., Schubert, K. O., & Baune, B. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813176-3.00043-2 · Cited by 2 · see citing works
Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders
Rahmoune, H., Martins‐de‐Souza, D., & Guest, P. C. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_4 · Cited by 2 · see citing works
Self-citationMicroRNAs in metabolic effects with atypical antipsychotics—a scoping review
Wu, W. T., Setiawan, D., Glatt, S. J., Chi, J., & Lin, P. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261430603 · Cited by 1 · see citing works
Flores, E. R. M., Cruz, B. F., Mantovani, L. M., & Salgado, J. V. (2026) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2026-1389 · Cited by 1 · see citing works
Mansfield, J. R., Guest, P. C., & Burks, J. K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_32 · Cited by 1 · see citing works
Self-citationBlood-based Biomarkers for Personalised Medicine Applications in Schizophrenia
Tomasik, J. (2014) · EUR Research Repository (Erasmus University Rotterdam)
Proteômica da esquizofrenia: busca por biomarcadores em plaquetas
Joaquim, H. P. G. (2018) · doi:10.11606/t.5.2018.tde-09042018-095856
Conundrums in Managing Early Stages of Schizophrenia
Palaniyappan, L. K., Sabesan, P., Norman, R. M. G., & Hasan, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70311-4_10
Luckhoff, H. K. (2021) · SUNScholar (Stellenbosch University)
Urine proteomic analysis of patients with schizophreniaPreprint
Zhao, C., Dong, F., Zhou, F., Huan, Y., Yang, J., & Gao, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.11.566683
Fasting insulinemia as biomarker of illness relapse in patients with severe mental illness?
Orsolini, L., Fiorani, M., Longo, G., Manfredi, E., Cavallo, L., Marpepa, B., Bellagamba, S., Corona, D., & Volpe, U. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107171
Biological Characteristics of Treatment Outcomes in Schizophrenia
Das, M., Chakraborty, S., Das, N., & Mehta, U. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_80-1
Biological Characteristics of Treatment Outcomes in Schizophrenia
Das, M., Chakraborty, S., Das, N., & Mehta, U. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_80
- Authors
- Schwarz, E., Guest, P. C., Steiner, J., Bogerts, B., & Bahn, S.
- Affiliations
- University of Cambridge (GB)
- Otto-von-Guericke-Universität Magdeburg (DE)
- Corresponding author
- Schwarz, E
- Bahn, S
- Venue
- Translational Psychiatry
- Published
- 2012-02-21
- Volume
- 2
- Issue
- 2
- Pages
- e82-e82
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC3309553
- OpenAlex
- W2038358884
- Cited by
- 91
- References
- 31
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 9 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 12 · 2016: 7 · 2015: 10 · 2014: 8 · 2013: 7 · 2012: 2
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (unspecified)
- Locations
- Translational Psychiatry (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Funders
- Stanley Medical Research Institute
- European Commission (223427)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- schizophrenia, serum biomarkers, treatment response prediction, recurrence prediction, symptom severity, antipsychotic-naive patients, multiplex immunoassay, biomarker panel, treatment course
- MeSH terms
- Adult, C-Reactive Protein, Cross-Sectional Studies, Female, Ferritins, Humans, Male, Middle Aged, Myoglobin, Prolactin, Psychiatric Status Rating Scales, Recurrence, Risk Factors, Schizophrenia, Antipsychotic Agents, Biomarkers, Body Mass Index, Treatment Outcome, Interleukin-16, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
